1-3 of 3
Michael S. Low
Close
Sort by
Journal Articles

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

Pasquale L. Fedele, Simon N. Willis, Yang Liao, Michael S. Low, Jai Rautela, David H. Segal, Jia-Nan Gong, Nicholas D. Huntington, Wei Shi, David C. S. Huang, George Grigoriadis, Julie Tellier, Stephen L. Nutt
Journal: Blood
Blood (2018) 132 (20): 2166–2178.
https://doi.org/10.1182/blood-2018-05-850727
Published: 2018
Includes: Supplemental data
Journal Articles

Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma

Michael P Gilbertson, MBBS,FRACP,FRCPA, Maciej Tatarczuch, BMBS, FRACP, FRCPA, Ashish Kumar Panigrahi, MBBS, Samuel Robinson, David Wong, PhD, Pasquale L. Fedele, FRACP, FRCPA, Gareth Gregory, MBBS,PhDFRACP,FRCPA, George Grigoriadis, MBBS PhDFRACP FRCPA, Michael S. Low, MBBS, Sushrut S. Patil, FRACP, FRCPA, Sumita Ratnasingham, FRACP, FRCPA, Jake Shortt, MBBS PhDFRACP FRCPA, Fathima Shahla Vilcassim, MBBS, FRACP, FRCPA, Jonathan Wong, MBBS, Sophie Lee, FRACP, FRCPA, PhD, Duncan P. Carradice, MBBS, FRCPA, FRACP, William E. P. Renwick, MBBS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1568.
https://doi.org/10.1182/blood.V130.Suppl_1.1568.1568
Published: 2017
Journal Articles

The Immunomodulatory Drugs, through Loss of Ikaros and Aiolos, Derepress CD38 and Functionally Synergise with Daratumumab

Pasquale L. Fedele, FRACP, FRCPA, Simon Willis, PhD, Michael S. Low, MBBS, Jai Rautela, PhD, David H. Segal, PhD, Jianan Gong, PhD, Yang Liao, PhD, Nicholas Huntington, PhD, Wei Shi, PhD, David Huang, MBBS PhD, George Grigoriadis, MBBS PhDFRACP FRCPA, Julie Tellier, PhD, Stephen Nutt, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1801.
https://doi.org/10.1182/blood.V130.Suppl_1.1801.1801
Published: 2017